Table 1.
Baseline characteristics and outcomes according to the type of oral anticoagulant treatment
| Variable | VKA (n = 64) | NOAC (n = 25) | P‐value |
|---|---|---|---|
| Baseline clinical characteristics | |||
| Age (years, median, IQR) | 70 (60–77) | 78 (70–81) | 0.005 |
| Males (%) | 65.6% | 52.0% | 0.234 |
| BMI (median, IQR) | 30 (25–33) | 27 (17–34) | 0.133 |
| CHA2DS2‐VASc score (median, IQR) | 4 (3–5) | 4 (4–6) | 0.017 |
| HAS‐BLED score (median, IQR) | 3 (2–3) | 2 (2–4) | 0.917 |
| Hypertension (%) | 92.1% | 96.0% | 0.519 |
| Diabetes (%) | 42.2% | 32.0% | 0.376 |
| Hyperlipidemia (%) | 50.0% | 48.0% | 0.865 |
| Heart failure (%) | 21.9% | 12.0% | 0.287 |
| Current smoking (%) | 10.9% | 4.0% | 0.304 |
| Coronary artery disease (%) | 31.2% | 32.0% | 0.945 |
| Chronic kidney disease (%) | 17.2% | 16.0% | 0.893 |
| Prior history of ischemic stroke (%) | 29.7% | 24.0% | 0.592 |
| Prior history of intracerebral hemorrhage (%) | 6.2% | 0% | 0.201 |
| Statin pretreatment (%) | 67.2% | 48.0% | 0.094 |
| Antiplatelet pretreatment (%) | 43.7% | 36.0% | 0.505 |
| NIHSS admission (median, IQR) | 5 (3–18) | 6 (3–12) | 0.487 |
| GCS admission (median, IQR) | 14 (8–15) | 14 (13–15) | 0.257 |
| SBP admission (mmHg, median, IQR) | 163 (147–190) | 175 (141–200) | 0.435 |
| DBP admission (mmHg, median, IQR) | 94 (80–99) | 91 (74–98) | 0.464 |
| Baseline Laboratory values | |||
| INR admission (median, IQR) | 2.4 (1.8–3.6) | 1.2 (1.1–1.6) | <0.001 |
| aPTT admission (sec, median, IQR) | 39 (33–42) | 30 (28–32) | <0.001 |
| Platelet count ×103/μL (median, IQR) | 192 (159–259) | 218 (184–270) | 0.217 |
| CrCl on admission (ml/min, median, IQR) | 60 (44–70) | 60 (45–75) | 0.291 |
| Baseline neuroimaging findings | |||
| Lobar hemorrhage (%) | 57.8% | 28.0% | 0.001 |
| Intraventricular hemorrhage (%) | 35.9% | 32.0% | 0.726 |
| Baseline ICH volume (cm3, median, IQR) | 11.3 (5.1–26.3) | 4.9 (2.1–22.1) | 0.051 |
| ICH score (median, IQR) | 1 (1–2) | 1 (1–2) | 0.635 |
| Severe ICH (%)a | 14.5% | 16.0% | 0.861 |
| CMB presence (%) | 51.6% | 48.0% | 0.763 |
| CMB number (median, IQR)b | 7 (4–11) | 2 (1–3) | <0.001 |
| CMB ≥5 (%) | 31.2% | 4.0% | 0.006 |
| CMB ≥10 (%) | 17.1% | 4.0% | 0.102 |
| 3T MRI | 39.1% | 36.0% | 0.789 |
| SWI sequence | 6.2% | 0% | 0.201 |
a
Defined as ICH score ≥2.
b
After excluding patients without CMB presence.